Allogene Therapeutics presents interim futility analysis for ALPHA3 CAR-T program at SITC 2026

Allogene Therapeutics presented an interim futility analysis for its ALPHA3 allogeneic CAR-T program at SITC 2026. The company also highlighted expansion of its allogeneic CAR-T portfolio, underscoring its push to broaden cancer treatment access.

Detected & updated continuously · Source: Nebula